- Home
- JXG vs NCNA Comparison
JXG vs NCNA Comparison
Compare JXG & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- NCNA
- Stock Information
- Founded
- JXG N/A
- NCNA 1997
- Country
- JXG China
- NCNA United Kingdom
- Employees
- JXG N/A
- NCNA N/A
- Industry
- JXG
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- NCNA Health Care
- Exchange
- JXG Nasdaq
- NCNA Nasdaq
- Market Cap
- JXG 4.6M
- NCNA 4.5M
- IPO Year
- JXG N/A
- NCNA 2017
- Fundamental
- Price
- JXG $1.03
- NCNA $0.04
- Analyst Decision
- JXG
- NCNA Buy
- Analyst Count
- JXG 0
- NCNA 2
- Target Price
- JXG N/A
- NCNA $25.00
- AVG Volume (30 Days)
- JXG 525.9K
- NCNA 301.1M
- Earning Date
- JXG 05-15-2025
- NCNA 08-18-2025
- Dividend Yield
- JXG N/A
- NCNA N/A
- EPS Growth
- JXG N/A
- NCNA N/A
- EPS
- JXG 0.86
- NCNA N/A
- Revenue
- JXG $49,840,288.00
- NCNA N/A
- Revenue This Year
- JXG N/A
- NCNA N/A
- Revenue Next Year
- JXG N/A
- NCNA N/A
- P/E Ratio
- JXG $1.19
- NCNA N/A
- Revenue Growth
- JXG 56.53
- NCNA N/A
- 52 Week Low
- JXG $0.55
- NCNA $0.03
- 52 Week High
- JXG $8.40
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- JXG N/A
- NCNA 39.10
- Support Level
- JXG N/A
- NCNA $0.04
- Resistance Level
- JXG N/A
- NCNA $0.07
- Average True Range (ATR)
- JXG 0.00
- NCNA 0.01
- MACD
- JXG 0.00
- NCNA 0.00
- Stochastic Oscillator
- JXG 0.00
- NCNA 25.00
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.